Literature DB >> 20091712

Transplantation of galectin-1-expressing human neural stem cells into the injured spinal cord of adult common marmosets.

Junichi Yamane1, Masaya Nakamura, Akio Iwanami, Masanori Sakaguchi, Hiroyuki Katoh, Masayuki Yamada, Suketaka Momoshima, Sachiyo Miyao, Ken Ishii, Norikazu Tamaoki, Tatsuji Nomura, Hirotaka James Okano, Yonehiro Kanemura, Yoshiaki Toyama, Hideyuki Okano.   

Abstract

Delayed transplantation of neural stem/progenitor cells (NS/PCs) into the injured spinal cord can promote functional recovery in adult rats and monkeys. To enhance the functional recovery after NS/PC transplantation, we focused on galectin-1, a carbohydrate-binding protein with pleiotropic roles in cell growth, differentiation, apoptosis, and neurite outgrowth. Here, to determine the combined therapeutic effect of NS/PC transplantation and galectin-1 on spinal cord injury (SCI), human NS/PCs were transfected by lentivirus with galectin-1 and green fluorescent protein (GFP), (Gal-NS/PCs) or GFP alone (GFP-NS/PCs), expanded in vitro, and then transplanted into the spinal cord of adult common marmosets, 9 days after contusive cervical SCI. The animals' motor function was evaluated by their spontaneous motor activity, bar grip power, and performance on a treadmill test. Histological analyses revealed that the grafted human NS/PCs survived and differentiated into neurons, astrocytes, and oligodendrocytes. There were significant differences in the myelinated area, corticospinal fibers, and serotonergic fibers among the Gal-NS/PC, GFP-NS/PC, vehicle-control, and sham-operated groups. The Gal-NS/PC-grafted animals showed a better performance on all the behavioral tests compared with the other groups. These findings suggest that Gal-NS/PCs have better therapeutic potential than NS/PCs for SCI in nonhuman primates and that human Gal-NS/PC transplantation might be a feasible treatment for human SCI. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20091712     DOI: 10.1002/jnr.22322

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  29 in total

1.  Glycan-dependent binding of galectin-1 to neuropilin-1 promotes axonal regeneration after spinal cord injury.

Authors:  H R Quintá; J M Pasquini; G A Rabinovich; L A Pasquini
Journal:  Cell Death Differ       Date:  2014-02-21       Impact factor: 15.828

Review 2.  Stem cells as drug delivery methods: application of stem cell secretome for regeneration.

Authors:  Christine Tran; Margot S Damaser
Journal:  Adv Drug Deliv Rev       Date:  2014-10-15       Impact factor: 15.470

3.  Allogeneic Neural Stem/Progenitor Cells Derived From Embryonic Stem Cells Promote Functional Recovery After Transplantation Into Injured Spinal Cord of Nonhuman Primates.

Authors:  Hiroki Iwai; Hiroko Shimada; Soraya Nishimura; Yoshiomi Kobayashi; Go Itakura; Keiko Hori; Keigo Hikishima; Hayao Ebise; Naoko Negishi; Shinsuke Shibata; Sonoko Habu; Yoshiaki Toyama; Masaya Nakamura; Hideyuki Okano
Journal:  Stem Cells Transl Med       Date:  2015-05-27       Impact factor: 6.940

Review 4.  Great promise of tissue-resident adult stem/progenitor cells in transplantation and cancer therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

5.  Galectin-1 in injured rat spinal cord: implications for macrophage phagocytosis and neural repair.

Authors:  Andrew D Gaudet; David R Sweet; Nicole K Polinski; Zhen Guan; Phillip G Popovich
Journal:  Mol Cell Neurosci       Date:  2014-12-24       Impact factor: 4.314

Review 6.  Advances in stem cell therapy for spinal cord injury.

Authors:  Andrea J Mothe; Charles H Tator
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

7.  Increases of Galectin-1 and its S-nitrosylated form in the Brain Tissues of Scrapie-Infected Rodent Models and Human Prion Diseases.

Authors:  Yan-Jun Guo; Qi Shi; Xiao-Dong Yang; Jian-Le Li; Yue Ma; Kang Xiao; Cao Chen; Jun Han; Xiao-Ping Dong
Journal:  Mol Neurobiol       Date:  2016-05-23       Impact factor: 5.590

Review 8.  Will stem cell therapies be safe and effective for treating spinal cord injuries?

Authors:  Katharine E Thomas; Lawrence D F Moon
Journal:  Br Med Bull       Date:  2011-05-17       Impact factor: 4.291

Review 9.  Gene delivery with viral vectors for cerebrovascular diseases.

Authors:  Yu Gan; Zheng Jing; Ruth Anne Stetler; Guodong Cao
Journal:  Front Biosci (Elite Ed)       Date:  2013-01-01

Review 10.  How stem cells speak with host immune cells in inflammatory brain diseases.

Authors:  Stefano Pluchino; Chiara Cossetti
Journal:  Glia       Date:  2013-04-30       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.